Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC)

Autores
Fernandez Calotti, Paula; Jordheim, Lars Petter; Giordano, Mirta Nilda; Dumontet, Charles; Galmarini, Carlos Maria
Año de publicación
2005
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Acute myelogenous leukemia (AML) is the most common form of acute leukemia in adults. After diagnosis, patients with AML are mainly treated with standard induction chemotherapy combining cytarabine (araC) and anthracyclines. The majority of them achieve complete remission (CR) (65-80%). However, prospects for long-term survival are poor for the majority of patients. Resistance to chemotherapy therefore remains a major obstacle in the effective treatment of patients with AML. In this review, we highlight the current knowledge of substrate cycles involved in normal deoxynucleoside triphosphate (dNTPs) metabolism and their possible role in drug resistance to araC. © 2005 Taylor & Francis Group Ltd.
Fil: Fernandez Calotti, Paula. Academia Nacional de Medicina de Buenos Aires; Argentina
Fil: Jordheim, Lars Petter. Université Claude Bernard Lyon 1; Francia
Fil: Giordano, Mirta Nilda. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Academia Nacional de Medicina de Buenos Aires; Argentina
Fil: Dumontet, Charles. Université Claude Bernard Lyon 1; Francia
Fil: Galmarini, Carlos Maria. Université Claude Bernard Lyon 1; Francia
Materia
Aml
Arac
Nucleotide Metabolism
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/62580
Acceder
id CONICETDig_4575a58045d9e3c854f7e29914681ee5
oai_identifier_str oai:ri.conicet.gov.ar:11336/62580
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC)Fernandez Calotti, PaulaJordheim, Lars PetterGiordano, Mirta NildaDumontet, CharlesGalmarini, Carlos MariaAmlAracNucleotide Metabolismhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Acute myelogenous leukemia (AML) is the most common form of acute leukemia in adults. After diagnosis, patients with AML are mainly treated with standard induction chemotherapy combining cytarabine (araC) and anthracyclines. The majority of them achieve complete remission (CR) (65-80%). However, prospects for long-term survival are poor for the majority of patients. Resistance to chemotherapy therefore remains a major obstacle in the effective treatment of patients with AML. In this review, we highlight the current knowledge of substrate cycles involved in normal deoxynucleoside triphosphate (dNTPs) metabolism and their possible role in drug resistance to araC. © 2005 Taylor & Francis Group Ltd.Fil: Fernandez Calotti, Paula. Academia Nacional de Medicina de Buenos Aires; ArgentinaFil: Jordheim, Lars Petter. Université Claude Bernard Lyon 1; FranciaFil: Giordano, Mirta Nilda. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Academia Nacional de Medicina de Buenos Aires; ArgentinaFil: Dumontet, Charles. Université Claude Bernard Lyon 1; FranciaFil: Galmarini, Carlos Maria. Université Claude Bernard Lyon 1; FranciaTaylor & Francis Ltd2005-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/62580Fernandez Calotti, Paula; Jordheim, Lars Petter; Giordano, Mirta Nilda; Dumontet, Charles; Galmarini, Carlos Maria; Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC); Taylor & Francis Ltd; Leukemia and Lymphoma; 46; 3; 3-2005; 335-3461042-8194CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1080/10428190400015683info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/abs/10.1080/10428190400015683info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:44:36Zoai:ri.conicet.gov.ar:11336/62580instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:44:36.699CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC)
title Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC)
spellingShingle Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC)
Fernandez Calotti, Paula
Aml
Arac
Nucleotide Metabolism
title_short Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC)
title_full Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC)
title_fullStr Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC)
title_full_unstemmed Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC)
title_sort Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC)
dc.creator.none.fl_str_mv Fernandez Calotti, Paula
Jordheim, Lars Petter
Giordano, Mirta Nilda
Dumontet, Charles
Galmarini, Carlos Maria
author Fernandez Calotti, Paula
author_facet Fernandez Calotti, Paula
Jordheim, Lars Petter
Giordano, Mirta Nilda
Dumontet, Charles
Galmarini, Carlos Maria
author_role author
author2 Jordheim, Lars Petter
Giordano, Mirta Nilda
Dumontet, Charles
Galmarini, Carlos Maria
author2_role author
author
author
author
dc.subject.none.fl_str_mv Aml
Arac
Nucleotide Metabolism
topic Aml
Arac
Nucleotide Metabolism
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Acute myelogenous leukemia (AML) is the most common form of acute leukemia in adults. After diagnosis, patients with AML are mainly treated with standard induction chemotherapy combining cytarabine (araC) and anthracyclines. The majority of them achieve complete remission (CR) (65-80%). However, prospects for long-term survival are poor for the majority of patients. Resistance to chemotherapy therefore remains a major obstacle in the effective treatment of patients with AML. In this review, we highlight the current knowledge of substrate cycles involved in normal deoxynucleoside triphosphate (dNTPs) metabolism and their possible role in drug resistance to araC. © 2005 Taylor & Francis Group Ltd.
Fil: Fernandez Calotti, Paula. Academia Nacional de Medicina de Buenos Aires; Argentina
Fil: Jordheim, Lars Petter. Université Claude Bernard Lyon 1; Francia
Fil: Giordano, Mirta Nilda. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Academia Nacional de Medicina de Buenos Aires; Argentina
Fil: Dumontet, Charles. Université Claude Bernard Lyon 1; Francia
Fil: Galmarini, Carlos Maria. Université Claude Bernard Lyon 1; Francia
description Acute myelogenous leukemia (AML) is the most common form of acute leukemia in adults. After diagnosis, patients with AML are mainly treated with standard induction chemotherapy combining cytarabine (araC) and anthracyclines. The majority of them achieve complete remission (CR) (65-80%). However, prospects for long-term survival are poor for the majority of patients. Resistance to chemotherapy therefore remains a major obstacle in the effective treatment of patients with AML. In this review, we highlight the current knowledge of substrate cycles involved in normal deoxynucleoside triphosphate (dNTPs) metabolism and their possible role in drug resistance to araC. © 2005 Taylor & Francis Group Ltd.
publishDate 2005
dc.date.none.fl_str_mv 2005-03
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/62580
Fernandez Calotti, Paula; Jordheim, Lars Petter; Giordano, Mirta Nilda; Dumontet, Charles; Galmarini, Carlos Maria; Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC); Taylor & Francis Ltd; Leukemia and Lymphoma; 46; 3; 3-2005; 335-346
1042-8194
CONICET Digital
CONICET
url http://hdl.handle.net/11336/62580
identifier_str_mv Fernandez Calotti, Paula; Jordheim, Lars Petter; Giordano, Mirta Nilda; Dumontet, Charles; Galmarini, Carlos Maria; Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC); Taylor & Francis Ltd; Leukemia and Lymphoma; 46; 3; 3-2005; 335-346
1042-8194
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1080/10428190400015683
info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/abs/10.1080/10428190400015683
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Taylor & Francis Ltd
publisher.none.fl_str_mv Taylor & Francis Ltd
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844614484058963968
score 13.070432

Publicaciones similares